Chris K Rayner Mbbs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5041957/publications.pdf

Version: 2024-02-01

191	7,241	47006	71685
papers	citations	47 h-index	76 g-index

194	194	194	5898
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes. Diabetes Care, 2009, 32, 1600-1602.	8.6	318
2	Effects of Fat on Gastric Emptying of and the Glycemic, Insulin, and Incretin Responses to a Carbohydrate Meal in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2062-2067.	3.6	286
3	Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones. Diabetes Care, 2013, 36, 1396-1405.	8.6	255
4	Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. American Journal of Physiology - Renal Physiology, 2009, 296, G735-G739.	3.4	201
5	Gastric emptying and glycaemia in health and diabetes mellitus. Nature Reviews Endocrinology, 2015, 11, 112-128.	9.6	197
6	Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 215-221.	3.6	196
7	Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E743-E753.	3.5	169
8	Roles of the Gut in Glucose Homeostasis. Diabetes Care, 2016, 39, 884-892.	8.6	155
9	Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. American Journal of Clinical Nutrition, 2012, 95, 78-83.	4.7	136
10	Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. Diabetes, 2014, 63, 785-790.	0.6	120
11	Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. British Journal of Nutrition, 2010, 104, 803-806.	2.3	117
12	Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. American Journal of Clinical Nutrition, 2007, 86, 1364-1368.	4.7	114
13	The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E647-E655.	3.5	109
14	Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management. Diabetes Care, 2018, 41, 627-637.	8.6	100
15	Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine. Diabetes, 2017, 66, 2144-2149.	0.6	99
16	Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after gastric bypass. Obesity, 2014, 22, 2003-2009.	3.0	98
17	Gastroparesis: Prevalence, Clinical Significance and Treatment. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 805-813.	1.7	97
18	Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition, 2016, 103, 66-70.	4.7	96

#	Article	IF	Citations
19	Effects of ginger on gastric emptying and motility in healthy humans. European Journal of Gastroenterology and Hepatology, 2008, 20, 436-440.	1.6	95
20	Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*. Critical Care Medicine, 2010, 38, 1261-1269.	0.9	88
21	Disordered Control of Intestinal Sweet Taste Receptor Expression and Glucose Absorption in Type 2 Diabetes. Diabetes, 2013, 62, 3532-3541.	0.6	88
22	Diabetic Gastroparesis. Drugs, 2009, 69, 971-986.	10.9	76
23	Gastric Emptying, Incretin Hormone Secretion, and Postprandial Glycemia in Cystic Fibrosisâ€"Effects of Pancreatic Enzyme Supplementation. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E851-E855.	3.6	76
24	Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Experimental Diabetes Research, 2011, 2011, 1-10.	3.8	75
25	Effects of Taurocholic Acid on Glycemic, Glucagon-like Peptide-1, and Insulin Responses to Small Intestinal Glucose Infusion in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E718-E722.	3.6	74
26	The Effects of Critical Illness on Intestinal Glucose Sensing, Transporters, and Absorption*. Critical Care Medicine, 2014, 42, 57-65.	0.9	74
27	Relationships of Early And Late Glycemic Responses With Gastric Emptying During An Oral Glucose Tolerance Test. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3565-3571.	3.6	72
28	A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. Diabetes Care, 2016, 39, 511-517.	8.6	72
29	Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology, 2016, 16, 164-180.	1.1	71
30	Pancreatic Enzyme Supplementation Improves the Incretin Hormone Response and Attenuates Postprandial Glycemia in Adolescents With Cystic Fibrosis: A Randomized Crossover Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2486-2493.	3.6	69
31	Gut motility and enteroendocrine secretion. Current Opinion in Pharmacology, 2013, 13, 928-934.	3.5	68
32	Whey protein: The â€œwheyâ€•forward for treatment of type 2 diabetes?. World Journal of Diabetes, 2015, 6, 1274.	3.5	64
33	Proximal Gastric Compliance and Perception of Distension in Type 1 Diabetes Mellitus: Effects of Hyperglycemia. American Journal of Gastroenterology, 2000, 95, 1175-1183.	0.4	61
34	Comparative Effects of Variations in Duodenal Glucose Load on Glycemic, Insulinemic, and Incretin Responses in Healthy Young and Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 844-851.	3.6	61
35	Mechanism of glucoseâ€lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes, Obesity and Metabolism, 2020, 22, 141-148.	4.4	60
36	Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?. Diabetes Research and Clinical Practice, 2014, 106, e3-e6.	2.8	59

#	Article	IF	Citations
37	Gastric Emptying in the Elderly. Clinics in Geriatric Medicine, 2015, 31, 339-353.	2.6	58
38	Augmented capacity for peripheral serotonin release in human obesity. International Journal of Obesity, 2018, 42, 1880-1889.	3.4	58
39	Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3311-3319.	3.6	58
40	Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E504-E507.	3.5	57
41	The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes, 2016, 65, 269-275.	0.6	56
42	Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited?. Journal of Clinical Investigation, 2006, 116, 299-302.	8.2	54
43	Upper and/or lower gastrointestinal adverse events with glucagonâ€like peptideâ€1 receptor agonists: <scp>I</scp>ncidence and consequences. Diabetes, Obesity and Metabolism, 2017, 19, 672-681.	4.4	53
44	Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease. Nutrients, 2021, 13, 1104.	4.1	53
45	A 25-Year Longitudinal Evaluation of Gastric Emptying in Diabetes. Diabetes Care, 2012, 35, 2594-2596.	8.6	52
46	Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes. Advances in Therapy, 2013, 30, 81-101.	2.9	52
47	Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans. Diabetes Care, 2013, 36, e202-e203.	8.6	51
48	Sustained effects of a protein â€˜preloadâ€™ on glycaemia and gastric emptying over 4 weeks in patients with type 2 diabetes: A randomized clinical trial. Diabetes Research and Clinical Practice, 2015, 108, e31-e34.	2.8	51
49	Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 290-293.	4.4	48
50	New management approaches for gastroparesis. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 454-462.	1.7	47
51	Physiology of the ageing gut. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 33-38.	2.5	46
52	Small Intestinal Glucose Exposure Determines the Magnitude of the Incretin Effect in Health and Type 2 Diabetes. Diabetes, 2014, 63, 2668-2675.	0.6	46
53	Dietary Effects on Incretin Hormone Secretion. Vitamins and Hormones, 2010, 84, 81-110.	1.7	45
54	Randomized double-blind crossover study to determine the effects of erythromycin on small intestinal nutrient absorption and transit in the critically ill. American Journal of Clinical Nutrition, 2012, 95, 1396-1402.	4.7	45

#	Article	IF	Citations
55	Effects of a D-Xylose Preload With or Without Sitagliptin on Gastric Emptying, Glucagon-Like Peptide-1, and Postprandial Glycemia in Type 2 Diabetes. Diabetes Care, 2013, 36, 1913-1918.	8.6	45
56	Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin. Diabetes, 2014, 63, 2776-2787.	0.6	45
57	Incretins. Handbook of Experimental Pharmacology, 2015, 233, 137-171.	1.8	45
58	Gastric Emptying Is More Rapid in Adolescents With Type 1 Diabetes and Impacts on Postprandial Glycemia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2248-2253.	3.6	44
59	Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index. American Journal of Physiology - Renal Physiology, 2014, 307, G958-G967.	3.4	43
60	An update on autonomic neuropathy affecting the gastrointestinal tract. Current Diabetes Reports, 2006, 6, 417-423.	4.2	42
61	Role of Intestinal Bitter Sensing in Enteroendocrine Hormone Secretion and Metabolic Control. Frontiers in Endocrinology, 2018, 9, 576.	3.5	42
62	Plasma endocannabinoid levels in lean, overweight, and obese humans: relationships to intestinal permeability markers, inflammation, and incretin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E489-E495.	3.5	41
63	Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American Journal of Physiology - Renal Physiology, 2007, 292, G1099-G1104.	3.4	39
64	Effects of Intraduodenal Glutamine on Incretin Hormone and Insulin Release, the Glycemic Response to an Intraduodenal Glucose Infusion, and Antropyloroduodenal Motility in Health and Type 2 Diabetes. Diabetes Care, 2013, 36, 2262-2265.	8.6	39
65	Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steadyâ€state concentrations. Diabetes, Obesity and Metabolism, 2020, 22, 788-797.	4.4	39
66	New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Review of Gastroenterology and Hepatology, 2017, 11, 157-166.	3.0	38
67	Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1158-1167.	4.4	38
68	Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care, 2019, 42, 520-528.	8.6	37
69	Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia, 2015, 58, 1769-1778.	6.3	36
70	Diabetic Gastroparesis and Its Impact on Glycemia. Endocrinology and Metabolism Clinics of North America, 2010, 39, 745-762.	3.2	35
71	Diabetic gastroparesisâ€"Backwards and forwards. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 46-57.	2.8	35
72	Effects of small intestinal glucose load on blood pressure, splanchnic blood flow, glycemia, and GLP-1 release in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1524-R1531.	1.8	35

#	Article	IF	Citations
73	A whey/guar â€œpreloadâ€•improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12â€•week, singleâ€blind, randomized, placeboâ€•controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 930-938.	4.4	35
74	Pathophysiology and management of gastroparesis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 167-181.	3.0	34
75	Measurement of gastric emptying in diabetes. Journal of Diabetes and Its Complications, 2014, 28, 894-903.	2.3	34
76	Associated factors in Streptococcus bovis bacteremia and colorectal cancer. Kaohsiung Journal of Medical Sciences, 2016, 32, 196-200.	1.9	34
77	Upper gastrointestinal function and glycemic control in diabetes mellitus. World Journal of Gastroenterology, 2006, 12, 5611.	3.3	34
78	Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2628-E2634.	3.6	32
79	Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagonâ€like peptideâ€1, and gastric emptying after oral glucose, in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 640-647.	4.4	31
80	Gastric Emptying, Diabetes, and Aging. Clinics in Geriatric Medicine, 2007, 23, 785-808.	2.6	30
81	Pathophysiology and Management of Diabetic Gastropathy. Drugs, 2007, 67, 1671-1687.	10.9	29
82	Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2019, 21, 700-704.	4.4	29
83	Effect of hyperglycemia on triggering of transient lower esophageal sphincter relaxations. American Journal of Physiology - Renal Physiology, 2004, 286, G797-G803.	3.4	26
84	Diabetic gastroparesis: recent insights into pathophysiology and implications for management. Expert Review of Gastroenterology and Hepatology, 2013, 7, 127-139.	3.0	26
85	Effects of gastric distension on blood pressure and superior mesenteric artery blood flow responses to intraduodenal glucose in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R960-R967.	1.8	24
86	Gut Mechanisms Linking Intestinal Sweet Sensing to Glycemic Control. Frontiers in Endocrinology, 2018, 9, 741.	3.5	24
87	Effects of mid-jejunal compared to duodenal glucose infusion on peptide hormone release and appetite in healthy men. Regulatory Peptides, 2008, 150, 38-42.	1.9	23
88	Insulin secretion in healthy subjects and patients with Type 2 diabetes â€“ role of the gastrointestinal tract. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 413-424.	4.7	23
89	Duodenal fatty acid sensor and transporter expression following acute fat exposure in healthy lean humans. Clinical Nutrition, 2017, 36, 564-569.	5.0	23
90	Diabetic Gastroparesis and Glycaemic Control. Current Diabetes Reports, 2019, 19, 153.	4.2	23

#	Article	IF	Citations
91	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. Pharmaceutics, 2020, 12, 790.	4.5	23
92	Effects of variations in duodenal glucose load on blood pressure, heart rate, superior mesenteric artery blood flow and plasma noradrenaline in healthy young and older subjects. Clinical Science, 2012, 122, 271-279.	4.3	22
93	Impact of gastric emptying to the glycemic and insulinemic responses to a 75-g oral glucose load in older subjects with normal and impaired glucose tolerance. Physiological Reports, 2014, 2, e12204.	1.7	22
94	Effects of Physiological Hyperglycemia on Duodenal Motility and Flow Events, Glucose Absorption, and Incretin Secretion in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3893-3900.	3.6	21
95	Title: Differentiating the effects of whey protein and guar gum preloads on postprandial glycemia in type 2 diabetes. Clinical Nutrition, 2019, 38, 2827-2832.	5.0	21
96	Effects of variations in intragastric volume on blood pressure and splanchnic blood flow during intraduodenal glucose infusion in healthy older subjects. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R391-R399.	1.8	20
97	The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill. Diabetes Care, 2013, 36, 3333-3336.	8.6	20
98	Hypoglycaemia and gastric emptying. Diabetes, Obesity and Metabolism, 2019, 21, 491-498.	4.4	20
99	Sugar Responses of Human Enterochromaffin Cells Depend on Gut Region, Sex, and Body Mass. Nutrients, 2019, 11, 234.	4.1	19
100	Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2020, 43, 1813-1821.	8.6	19
101	Decreased Gastric Motility in Type II Diabetic Patients. BioMed Research International, 2014, 2014, 1-6.	1.9	18
102	Glucose absorption in small intestinal diseases. Expert Review of Gastroenterology and Hepatology, 2014, 8, 301-312.	3.0	18
103	Effects of Fat and Protein Preloads on Pouch Emptying, Intestinal Transit, Glycaemia, Gut Hormones, Glucose Absorption, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass. Obesity Surgery, 2016, 26, 77-84.	2.1	17
104	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4409-4418.	3.6	17
105	Glucagonâ€like peptideâ€1 receptor agonists and the appropriate measurement of gastric emptying. Diabetes, Obesity and Metabolism, 2020, 22, 2504-2506.	4.4	17
106	Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males. Peptides, 2017, 95, 124-127.	2.4	16
107	Gastrointestinal autonomic neuropathy in diabetes. Autonomic Neuroscience: Basic and Clinical, 2020, 229, 102718.	2.8	16
108	Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1450-1456.	2.8	16

#	Article	IF	Citations
109	Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E830-E837.	3.5	15
110	Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control. Biomarkers in Medicine, 2016, 10, 1167-1179.	1.4	15
111	Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6201-6206.	3.6	15
112	Role of intestinal glucose absorption in glucose tolerance. Current Opinion in Pharmacology, 2020, 55, 116-124.	3.5	15
113	Plasma GLP-1 Response to Oral and Intraduodenal Nutrients in Health and Type 2 Diabetesâ€"Impact on Gastric Emptying. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1643-e1652.	3.6	15
114	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4769-4778.	3.6	14
115	Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. Diabetes Care, 2017, 40, 702-705.	8.6	14
116	Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 51-58.	4.4	14
117	Gastric emptying in health and type 2 diabetes: An evaluation using a 75Âg oral glucose drink. Diabetes Research and Clinical Practice, 2021, 171, 108610.	2.8	14
118	Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 59-63.	2.0	13
119	Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients, 2020, 12, 1962.	4.1	13
120	Expression of sweet taste receptor and gut hormone secretion in modelled type 2 diabetes. General and Comparative Endocrinology, 2017, 252, 142-149.	1.8	12
121	Is Making the Stomach Pump Better the Answer to Gastroparesis?. Gastroenterology, 2019, 156, 1555-1557.	1.3	12
122	Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1251-1254.	4.4	12
123	Gastrointestinal adverse events with insulin glargine/lixisenatide fixedâ€ratio combination versus glucagonâ€like peptideâ€1 receptor agonist<scp>s</scp> in people with type 2 diabetes mellitus: A network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 136-146.	4.4	12
124	Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. Regulatory Peptides, 2008, 146, 1-3.	1.9	11
125	Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. American Journal of Physiology - Renal Physiology, 2010, 299, G1326-G1333.	3.4	11
126	Novel insights into the effects of diabetes on gastric motility. Expert Review of Gastroenterology and Hepatology, 2016, 10, 581-593.	3.0	11

#	Article	IF	Citations
127	Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. Physiological Reports, 2017, 5, e13122.	1.7	11
128	Disparities in gastric emptying and postprandial glycaemia between Han Chinese and Caucasians with type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107951.	2.8	11
129	Increasing Helicobacter pylori clarithromycin resistance in Australia over 20â€‰years. Internal Medicine Journal, 2022, 52, 1554-1560.	0.8	11
130	Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial. Nutrition, 2016, 32, 553-559.	2.4	10
131	Comparative Effects of Bile Diversion and Duodenal-Jejunal Bypass on Glucose and Lipid Metabolism in Male Diabetic Rats. Obesity Surgery, 2016, 26, 1565-1575.	2.1	10
132	Role of endogenous glucagonâ€like peptideâ€1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 383-392.	4.4	10
133	A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans. Gastroenterology, 2021, 161, 536-547.e2.	1.3	10
134	Changes in meal composition and duration affect postprandial endothelial function in healthy humans. American Journal of Physiology - Renal Physiology, 2014, 307, G1191-G1197.	3.4	9
135	Gut feelings about diabetes and <scp>GLP</scp>â€1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders. Diabetes, Obesity and Metabolism, 2017, 19, 309-312.	4.4	9
136	Combination of laser and human adipose-derived stem cells in repair of rabbit anal sphincter injury: a new therapeutic approach. Stem Cell Research and Therapy, 2019, 10, 367.	5.5	9
137	The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects. Nutrients, 2019, 11, 2666.	4.1	9
138	Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. Nutrients, 2021, 13, 2826.	4.1	9
139	Comparison of Cap-Assisted vs Conventional Endoscopic Technique for Management of Food Bolus Impaction in the Esophagus: Results of a Multicenter Randomized Controlled Trial. American Journal of Gastroenterology, 2021, 116, 2235-2240.	0.4	9
140	Nutrition Management for Critically Ill Adult Patients Requiring Non-Invasive Ventilation: A Scoping Review. Nutrients, 2022, 14, 1446.	4.1	9
141	Longitudinal evaluation of gastric emptying in type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 154, 27-34.	2.8	8
142	Sucralose can improve glucose tolerance and upregulate expression of sweet taste receptors and glucose transporters in an obese rat model. European Journal of Nutrition, 2021, 60, 1809-1817.	3.9	8
143	Development of innovative tools for investigation of nutrient-gut interaction. World Journal of Gastroenterology, 2020, 26, 3562-3576.	3.3	8
144	Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit. Diabetes, Obesity and Metabolism, 2022, 24, 1182-1184.	4.4	8

#	Article	IF	Citations
145	Upper gastrointestinal responses to intraduodenal nutrient in type 1 diabetes mellitus. European Journal of Gastroenterology and Hepatology, 2004, 16, 183-189.	1.6	7
146	Glucagon receptor signalling â€“ backwards and forwards. Expert Opinion on Investigational Drugs, 2018, 27, 135-138.	4.1	7
147	Effects of intraduodenal administration of the artificial sweetener sucralose on blood pressure and superior mesenteric artery blood flow in healthy older subjects. American Journal of Clinical Nutrition, 2018, 108, 156-162.	4.7	7
148	Effects of Glutamine on Gastric Emptying of Low- and High-Nutrient Drinks in Healthy Young Subjectsâ€”Impact on Glycaemia. Nutrients, 2018, 10, 739.	4.1	7
149	Measurement of Gastric Emptying Using a 13C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 751-757.	1.2	7
150	Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2â€hour plasma glucose in individuals without diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1132-1142.	4.4	7
151	Geospatial analysis of <scp>Helicobacter pylori</scp> infection in South Australia: Should location influence eradication therapy?. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1263-1274.	2.8	7
152	Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3850-e3856.	3.6	7
153	Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans. Regulatory Peptides, 2010, 159, 156-159.	1.9	6
154	Physiology of the Antral Pump and Gastric Emptying. , 2012, , 959-976.		6
155	Agonism of receptors in the gutâ€“pancreas axis in type 2 diabetes: are two better than one?. Lancet, The, 2018, 391, 2577-2578.	13.7	6
156	A Multiplexed Microfluidic Platform toward Interrogating Endocrine Function: Simultaneous Sensing of Extracellular Ca²⁺ and Hormone. ACS Sensors, 2020, 5, 490-499.	7.8	6
157	Acceleration of Gastric Emptying by Insulin-Induced Hypoglycemia is Dependent on the Degree of Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 364-371.	3.6	6
158	Cholecystectomy is associated with dysglycaemia: Crossâ€sectional and prospective analyses. Diabetes, Obesity and Metabolism, 2022, 24, 1656-1660.	4.4	6
159	Gastric Emptying and the Personalized Management of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3503-3506.	3.6	5
160	The prevalence and impact of low faecal elastase-1 in community-based patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 156, 107822.	2.8	5
161	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. Acta Diabetologica, 2020, 57, 583-587.	2.5	5
162	Spontaneous or Deliberate: Effects of Acute Variations in Glycemia on Gastric Emptying in Type 1 Diabetes. Diabetes Care, 2021, 44, 316-318.	8.6	5

#	Article	IF	Citations
163	DPP-4 Inhibition and the Known Unknown. Diabetes, 2016, 65, 2124-2126.	0.6	4
164	A randomized, crossover study of the acute effects of acarbose and gastric distension, alone and combined, on postprandial blood pressure in healthy older adults. BMC Geriatrics, 2019, 19, 241.	2.7	4
165	Secretion of Gut Hormones and Expression of Sweet Taste Receptors and Glucose Transporters in a Rat Model of Obesity. Obesity Facts, 2019, 12, 190-198.	3.4	4
166	Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. Pharmaceuticals, 2020, 13, 410.	3.8	4
167	Effects of Proximal and Distal Enteral Glucose Infusion on Cardiovascular Response in Health and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2877-e2884.	3.6	4
168	The diabetic gut â€“ both aching and unfeeling?. Pain, 2007, 131, 239-240.	4.2	3
169	Regional specificity of the gut-incretin response to small intestinal glucose infusion in healthy older subjects. Peptides, 2016, 86, 126-132.	2.4	3
170	Effect of duodenal glucose load on blood pressure in type 2 diabetes. Diabetes Research and Clinical Practice, 2016, 113, 38-40.	2.8	3
171	Targeting postprandial glycaemia in children with diabetes: <scp>O</scp>pportunities and challenges. Diabetes, Obesity and Metabolism, 2018, 20, 766-774.	4.4	3
172	Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 326, 1213.	7.4	3
173	Ethnic disparities in insulin and glucose-dependent insulinotropic peptide (GIP) responses to intraduodenal glucose in health. Acta Diabetologica, 2015, 52, 817-819.	2.5	2
174	Gastrointestinal motility in people with type 1 diabetes and peripheral neuropathy. Diabetologia, 2017, 60, 2312-2313.	6.3	2
175	Whey Protein and Diabetes. , 2017, , 197-209.		2
176	Comparative Effects of Intraduodenal Glucose and Fat Infusion on Blood Pressure and Heart Rate in Type 2 Diabetes. Frontiers in Nutrition, 2020, 7, 582314.	3.7	2
177	Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2411-2413.	4.4	2
178	Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in TypeÂ2 Diabetes, Associated with Slowing of Gastric Emptying. Diabetes Therapy, 2022, 13, 1245-1249.	2.5	2
179	Reactive hypoglycaemia with seizure following intraduodenal glucose infusion in a patient with type 2 diabetes. Acta Diabetologica, 2017, 54, 215-218.	2.5	1
180	Comparative effects of small intestinal glucose on blood pressure, heart rate, and noradrenaline responses in obese and healthy subjects. Physiological Reports, 2018, 6, e13610.	1.7	1

#	Article	IF	Citations
181	Twincretin therapy for type 2 diabetes: how do two do?. Lancet, The, 2021, 398, 560-561.	13.7	1
182	Diabetic gastroparesis. , 2021, , 237-253.		1
183	Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509â€“2518. Diabetes Care, 2021, 44, e194-e195.	8.6	1
184	Effects of ileal glucose infusion on enteropancreatic hormone secretion in humans: relationship to glucose absorption. Metabolism: Clinical and Experimental, 2022, 131, 155198.	3.4	1
185	Protein â€˜pre-loadsâ€™ in type 2 diabetes: what do we know and what do we need to find out?. Diabetologia, 2014, 57, 2603-2604.	6.3	0
186	Comment on Russell-Jones et al. Diabetes Care 2017;40:943â€“950. Comment on Bowering et al. Diabetes Care 2017;40:951â€“957. Diabetes Care, 2018, 41, e27-e28.	8.6	0
187	Impact of variations in duodenal glucose load on insulin clearance in health and type 2 diabetes. Acta Diabetologica, 2018, 55, 205-207.	2.5	0
188	Statins and glycaemic control in type 2 diabetes: Are bile acids relevant?. British Journal of Clinical Pharmacology, 2020, 86, 2538-2539.	2.4	0
189	Diabetic Gastroparesis. , 2012, , 177-190.		0
190	Letter to the Editor: One-Hour Postload Hyperglycemia is a Stronger Predictor of Type 2 Diabetes than Impaired Fasting Glucose. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L33-L34.	3.6	0
191	Sensing Intraâ€•and Extraâ€Cellular Ca²⁺ in the Islet of Langerhans. Advanced Functional Materials, 2022, 32, 2106020.	14.9	0